Alume Biosciences: Funding, Investors & Team (Sep 2026)
Alume is a biotechnology company, developing nerve-targeted pharmaceutical agents for surgical and therapeutic use. The company's first product, ALM-488, is a fluorescently labeled peptide-dye conjugate that makes human nerves "glow," helping surgeons reduce injury to critical nerves during surgery. During surgery, inadvertent injury to nerves leads to loss of function, including paralysis, numbness, and decreased quality of life. Alume intends to develop agents including ALM-488 to be used as an adjunct during surgery to help surgeons see nerves better compared to current visualization with white light alone. Alume's technology has the potential to improve the accuracy of nerve identification, decrease operative time, and lead to better outcomes for patients.
Alume Biosciences has raised $21.9M across 3 funding rounds on record, the most recent a Series B of $13.0M announced in Jan 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Alume Biosciences Company Profile and Key Stats
Latest funding round on record: Jan 2023.
Alume Biosciences Funding Rounds
Alume Biosciences raised $5.5M in an undisclosed round announced in May 2020.
2.3 years later, a Grant of $3.4M was announced in Sep 2022.
4 months later, a Series B of $13.0M was announced in Jan 2023.
Alume Biosciences Founders and Leadership Team
Contact details for the Alume Biosciences team: 1 of 1 has an email address on file.
Start 14-day free trial →Alume Biosciences Funding Compared to Other Biotechnology Startups
Alume Biosciences' latest round of $13.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Alume Biosciences in Biotechnology and San Diego
Companies Similar to Alume Biosciences
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Alume Biosciences Funding FAQs
What does Alume Biosciences do?
Alume is a biotechnology company, developing nerve-targeted pharmaceutical agents for surgical and therapeutic use. The company's first product, ALM-488, is a fluorescently labeled peptide-dye conjugate that makes human nerves "glow," helping surgeons reduce injury to critical nerves during surgery. During surgery, inadvertent injury to nerves leads to loss of function, including paralysis, numbness, and decreased quality of life. Alume intends to develop agents including ALM-488 to be used as an adjunct during surgery to help surgeons see nerves better compared to current visualization with white light alone. Alume's technology has the potential to improve the accuracy of nerve identification, decrease operative time, and lead to better outcomes for patients.
How much funding has Alume Biosciences raised?
Alume Biosciences has raised $21.9M across 3 rounds on record. The most recent is a Series B of $13.0M announced in Jan 2023.
When did Alume Biosciences last raise funding?
Alume Biosciences' most recent funding round on record is a Series B of $13.0M, announced in Jan 2023.
Who is the CEO of Alume Biosciences?
Quyen Nguyen is listed as CEO at Alume Biosciences.
Where is Alume Biosciences headquartered?
Alume Biosciences is based in San Diego, California, United States.
How many employees does Alume Biosciences have?
Alume Biosciences is in the 11-50 employee band.
How does Alume Biosciences' funding compare to other Biotechnology startups?
Alume Biosciences' latest round of $13.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Alume Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Alume Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.